Trends in Transfemoral Aortic Valve Implantation Related Thrombocytopenia.

TAVI aortic valve contemporaneous thrombocytopenia transfemoral aortic valve replacement trends

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
29 Jan 2022
Historique:
received: 18 11 2021
revised: 14 12 2021
accepted: 17 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

TAVI related thrombocytopenia (TAVI-rTP) is still very common. The aim of this study was to compare the incidence, characteristics and impact of reduced platelet counts (RPC) after TAVI between an earlier and contemporary period. the patients enrolled were those experiencing severe symptomatic aortic stenosis who underwent TAVI between January 2010 and December 2019. The exclusion criteria were no available blood tests and periprocedural death. 334 patients (mean age 81.9 ± 6.7 years) were enrolled. For the earlier period, the mean RPC was 33 ± 15%, and in the contemporary period (2016-2019) it was 26 ± 14%. In the early group, we found that 62% of the patients had decreased platelet counts of more or equal to 30% in comparison to 33% in the contemporary period. The time of the procedure and the amount of the contrast that had been used in the later period were associated with significant RPCs ( contemporary TAVI-rTP continued to be a common phenomenon in our cohort. However, severe thrombocytopenia was significantly less frequent. An RPC of 30% or more is associated with a poor 30-day outcome.

Sections du résumé

BACKGROUND BACKGROUND
TAVI related thrombocytopenia (TAVI-rTP) is still very common. The aim of this study was to compare the incidence, characteristics and impact of reduced platelet counts (RPC) after TAVI between an earlier and contemporary period.
METHODS METHODS
the patients enrolled were those experiencing severe symptomatic aortic stenosis who underwent TAVI between January 2010 and December 2019. The exclusion criteria were no available blood tests and periprocedural death.
RESULTS RESULTS
334 patients (mean age 81.9 ± 6.7 years) were enrolled. For the earlier period, the mean RPC was 33 ± 15%, and in the contemporary period (2016-2019) it was 26 ± 14%. In the early group, we found that 62% of the patients had decreased platelet counts of more or equal to 30% in comparison to 33% in the contemporary period. The time of the procedure and the amount of the contrast that had been used in the later period were associated with significant RPCs (
CONCLUSION CONCLUSIONS
contemporary TAVI-rTP continued to be a common phenomenon in our cohort. However, severe thrombocytopenia was significantly less frequent. An RPC of 30% or more is associated with a poor 30-day outcome.

Identifiants

pubmed: 35160176
pii: jcm11030726
doi: 10.3390/jcm11030726
pmc: PMC8836837
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):118-29
pubmed: 25204308
EuroIntervention. 2012 Sep;8 Suppl Q:Q83-7
pubmed: 22995118
EuroIntervention. 2017 Sep 24;13(AA):AA11-AA21
pubmed: 28942382
Am J Cardiol. 2013 Jun 1;111(11):1619-24
pubmed: 23523059
ASAIO J. 2008 Jan-Feb;54(1):64-72
pubmed: 18204318
Am J Cardiol. 2019 Apr 1;123(7):1120-1126
pubmed: 30709598
Catheter Cardiovasc Interv. 2014 Mar 1;83(4):633-41
pubmed: 24123706
J Clin Med. 2021 Sep 15;10(18):
pubmed: 34575259
J Invasive Cardiol. 2016 May;28(5):210-6
pubmed: 27145054
Circulation. 2002 Dec 10;106(24):3006-8
pubmed: 12473543
Eur Heart J. 2014 Oct 7;35(38):2663-71
pubmed: 24598983
EuroIntervention. 2014 Sep;10 Suppl U:U90-U100
pubmed: 25256338
Eur J Heart Fail. 2018 Apr;20(4):642-650
pubmed: 29368369
Catheter Cardiovasc Interv. 2021 Jul 1;98(1):E139-E144
pubmed: 33058433
Cardiology. 2018;139(3):151-158
pubmed: 29353286
Eur J Cardiothorac Surg. 2017 Oct 1;52(4):616-664
pubmed: 29156023
Eur Heart J. 2012 Jun;33(12):1459-68
pubmed: 22285582
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):130-7
pubmed: 24677617
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732

Auteurs

Haitham Abu Khadija (H)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Gera Gandelman (G)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Omar Ayyad (O)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Lion Poles (L)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Michael Jonas (M)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Offir Paz (O)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Jacob George (J)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Alex Blatt (A)

Heart Center, Kaplan Medical Center, Rehovot 76100, Israel.
Mediciene Faculty, Hebrew University, Jerusalem 91120, Israel.

Classifications MeSH